Discussions with leaders: Johannes Czernin talks with Mike Sathekge, a nuclear medicine leader in South Africa, about challenges and promise for nuclear medicine practice and technology in Africa
Page 593
PSMA PET for prostate cancer: colleagues provide a state-of-the-art overview of the latest literature on current and emerging indications for prostate-specific membrane antigen PET imaging, as well as recommended interpretation criteria.
Page 596
Evaluation of biomarker cut points: Polley and Dignam review common statistical issues related to biomarker cut point identification and offer guidance on proper evaluation, interpretation, and validation.
Page 605
Tau and cognition: Tanner and Rabinovici look at tau imaging for in vivo visualization of molecular pathology in Alzheimer disease and at enhanced precision medicine approaches enabled by correlation of imaging with cognitive status and clinical severity.
Page 612
99mTc-Tilmanocept and SLN biopsy: Vidal-Sicart and colleagues describe multi-institutional results with 99mTc-tilmanocept in a heterogeneous group of breast cancer patients undergoing varied protocols for sentinellymph node biopsy.
Page 620
18F-FLT PET/CT in lung cancer relapse: Christensen and colleagues investigate the value added by 18F-FLT PET/CT to 18F-FDG PET/CT in diagnosis of relapse after definitive radiotherapy in patients with lung cancer.
Page 628
18F-FES PET in endometrial cancer: Yamada and colleagues evaluate the potential of 16α-18F-fluoro-17β-estradiol PET for predicting outcomes and possibly guiding treatment in patients with endometrial cancer and compare these results with those from 18F-FDGPET/CT
Page 636
PET/CT in UrC-ADC: Das and colleagues report on the effect of 18F-FDG PET/CT on management of patients with urachal adenocarcinoma, with a focus on identification of metastatic disease not appreciated on anatomic imaging.
Page 643
PAMI and lymph node metastasis: Nishio and colleagues assess photoacoustic molecular imaging of panitumumab, conjugated to a near-infrared fluorescent dye, for identification of occult metastatic lymph nodes in head and neck squamous cell carcinoma.
Page 648
Imaging therapeutic modulation of PD-L1: Jung and colleagues detail the development of an 89Zr-labeled anti—programmed death ligand 1 immune PET tracer that can monitor chemotherapy-mediated modulation of tumor PD-L1 expression in living subjects.
Page 656
11C-PS13 for COX-1 imaging in cancer: Boyle and colleagues consider the repurposing of 11C-PS13, a cyclooxygenase-1 PET neuroimaging radiopharmaceutical, in an ovarian cancer—xenografted mouse model.
Page 665
225Ac-PSMA I&T for mCRPC: Zacherl and colleagues detail clinical data on patients with advanced metastatic castration-resistant prostate cancer who underwent both imaging and targeted a-therapy with 225Ac-prostate-specific membrane antigen.
Page 669
PSMA PET in PCWG3: Farolfi and colleagues assess the screening impact of prostate-specific membrane antigen PET on the Prostate Cancer Clinical Trials Working Group 3 clinical subtype classification for castrationresistant prostate cancer when compared with conventional imaging.
Page 675
18F-rhPSMA-7.3 dosimetry: Tolvanen and colleagues report on a first-in-humans study of the safety, biodistribution, and radiation dosimetry of this novel 18F-labeled radiohybrid prostate-specific membrane antigen PET imaging agent.
Page 679
MIBG and neuroendocrine tumors: Yoshinaga and colleagues describe the effects of repeated 131I-meta-iodobenzylguanidine therapy on tumor size and tumor metabolic response in patients with metastatic neuroendocrine tumors.
Page 685
Prostate cancer, PET, and disparities: Bucknor and colleagues investigate potential differences in imaging access for patients receiving 18F-fluciclovine or 68Ga-prostate-specific membrane antigen for biochemically recurrent prostate cancer at a tertiary medical center.
Page 695
BAT radiomic repeatability: Nazeri and colleagues explore the repeatability of activated brown adipose tissue radiomic features on imaging as well as the impact of reconstruction methods and imaging modality choice.
Page 700
PET radiomic feature repeatability: Crandall and colleagues assess the test—retest repeatability of radiomic features extracted from 18F-FDG PET images of cervical tumors and explore the effects of different image preprocessing methods.
Page 707
Absolute 99mTc-pyrophosphate quantitation: Dorbala and colleagues determine correlations between absolute quantitative 99mTcpyrophosphate metrics using a novel SPECT/CT system and traditional measures of cardiac amyloid burden and also assess intraobserver repeatability of the quantitative metrics.
Page 716
(±)-11C-YJH08 PET and GR expression: Huang and colleagues report on basic and preclinical studies with this novel PET tracer targeted at measuring glucocorticoid receptor expression.
Page 723
PET quantitative bias in vivo: Lodge and colleagues use data acquired from patient volunteers to characterize bias in underlying PET imaging data, with results that provide additional support for use of quantitative imaging biomarkers.
Page 732
Fast total-body PET parametric imaging: Feng and colleagues describe a method to acquire whole-body 18F-FDG PET parametric images using only the first 90 seconds of postinjection scan data from a recently developed total-body PET system.
Page 738
- © 2021 by the Society of Nuclear Medicine and Molecular Imaging.
Jump to section
Related Articles
Cited By...
- No citing articles found.